End-hole Versus Microvalve Infusion Catheters in Patients Undergoing Drug-Eluting Microspheres-TACE for Solitary Hepatocellular Carcinoma Tumors: A Retrospective Analysis
Adult
Male
Carcinoma, Hepatocellular
Premedication
Antineoplastic Agents
Cohort Studies
03 medical and health sciences
0302 clinical medicine
Humans
Clinical Investigation
Chemoembolization, Therapeutic
Aged
Retrospective Studies
Liver Neoplasms
Equipment Design
Middle Aged
Microspheres
Liver Transplantation
3. Good health
Survival Rate
Treatment Outcome
Female
Neoplasm Recurrence, Local
Vascular Access Devices
DOI:
10.1007/s00270-018-2150-6
Publication Date:
2019-01-11T12:07:45Z
AUTHORS (12)
ABSTRACT
Pre-transplant locoregional therapy for hepatocellular carcinoma (HCC) during bridge-to-transplant impacts recurrence and survival rates following liver transplantation. Optimizing the effectiveness of transarterial chemoembolization (TACE) in this population is imperative, microvalve infusion catheters offer a means such improvement. All treatment-naive patients with solitary HCC tumors < 6.5 cm who underwent drug-eluting microspheres (DEM) TACE between 04/2015 08/2017 were retrospectively reviewed. Eighty-eight included DEM-TACE either standard end-hole (EH) or (MVI). The EH (n = 70) MVI 18) cohorts had similar baseline tumor size, laboratory values, etiologies. Initial objective response significantly higher vs. (100% 76.5%, p 0.019). There was no difference adverse events groups (p 0.265). exhibited lower AST 0.003) ALT 0.044) at 6 months. Blinded pathological analysis explanted livers showed greater concentrations within relative to surrounding tissue explants (88.7 ± 10.6%) versus (55.3 32.7%) 0.002). percentage necrosis group (89.0 2.2%) compared (56.1 44.5%) 0.006). In retrospective study single-center cohort, procedures associated improved response, increased deposition tissue, explant those performed using catheters.
SUPPLEMENTAL MATERIAL
Coming soon ....
REFERENCES (30)
CITATIONS (16)
EXTERNAL LINKS
PlumX Metrics
RECOMMENDATIONS
FAIR ASSESSMENT
Coming soon ....
JUPYTER LAB
Coming soon ....